Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
ISIN : US58933Y1055
Total Employee Number:
75,000Compare
Compare
Traded in other countries / regions
MRK.USA0QAH.UKMRK.CanadaMRK.MexicoMRK.ArgentinaMRCK34.Brazil6MK.GermanyMRK.Austria1MRKX.ItalyMRK.PeruMRK.ChileMRK.Switzerland6MK.BulgariaMRK.Ukraine Index Membership
Dow 30S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
1949-04-20Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 1.07 | |||||
Debt-to-EBITDA | 2.53 | |||||
Interest Coverage | 8.52 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.87 | |||||
Beneish M-Score | -2.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.6 | |||||
3-Year EBITDA Growth Rate | 10.4 | |||||
3-Year EPS without NRI Growth Rate | 6.3 | |||||
3-Year FCF Growth Rate | -5.2 | |||||
3-Year Book Growth Rate | 5.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.87 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.87 | |||||
9-Day RSI | 49.79 | |||||
14-Day RSI | 52.83 | |||||
3-1 Month Momentum % | -0.92 | |||||
6-1 Month Momentum % | 9.97 | |||||
12-1 Month Momentum % | 42.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.3 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.21 | |||||
Days Inventory | 137.75 | |||||
Days Sales Outstanding | 65.2 | |||||
Days Payable | 85.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.77 | |||||
Dividend Payout Ratio | 0.61 | |||||
3-Year Dividend Growth Rate | 5.4 | |||||
Forward Dividend Yield % | 2.81 | |||||
5-Year Yield-on-Cost % | 3.65 | |||||
3-Year Average Share Buyback Ratio | 0.8 | |||||
Shareholder Yield % | 2.07 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 73.91 | |||||
Operating Margin % | 19.72 | |||||
Net Margin % | 13.59 | |||||
EBITDA Margin % | 29.5 | |||||
FCF Margin % | 21.46 | |||||
OCF Margin % | 27.2 | |||||
ROE % | 18.04 | |||||
ROA % | 7.12 | |||||
ROIC % | 11.18 | |||||
3-Year ROIIC % | 14.23 | |||||
ROC (Joel Greenblatt) % | 46.03 | |||||
ROCE % | 13.35 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 34.16 | |||||
Forward PE Ratio | 41.9 | |||||
PE Ratio without NRI | 22.17 | |||||
Shiller PE Ratio | 29.87 | |||||
Price-to-Owner-Earnings | 55.77 | |||||
PEG Ratio | 1.4 | |||||
PS Ratio | 4.6 | |||||
PB Ratio | 6.53 | |||||
Price-to-Free-Cash-Flow | 21.42 | |||||
Price-to-Operating-Cash-Flow | 16.91 | |||||
EV-to-EBIT | 26.08 | |||||
EV-to-Forward-EBIT | 25.38 | |||||
EV-to-EBITDA | 17.68 | |||||
EV-to-Forward-EBITDA | 18.46 | |||||
EV-to-Revenue | 5.22 | |||||
EV-to-Forward-Revenue | 5.25 | |||||
EV-to-FCF | 24.3 | |||||
Price-to-GF-Value | 1.02 | |||||
Price-to-Projected-FCF | 1.86 | |||||
Price-to-Median-PS-Value | 1.04 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.54 | |||||
Earnings Yield (Greenblatt) % | 3.83 | |||||
FCF Yield % | 4.71 | |||||
Forward Rate of Return (Yacktman) % | 18.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:MRK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merck & Co Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 65,768 | ||
| EPS (TTM) ($) | 3.55 | ||
| Beta | -0.0608 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 27.79 | ||
| 14-Day RSI | 52.83 | ||
| 14-Day ATR ($) | 3.337932 | ||
| 20-Day SMA ($) | 122.765 | ||
| 12-1 Month Momentum % | 42.81 | ||
| 52-Week Range ($) | 76.66 - 130.29 | ||
| Shares Outstanding (Mil) | 2,469.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merck & Co Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merck & Co Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-29 | In 107 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 107 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 09:00 | In 22 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 21 days | ||
| USD 0.850000 Cash Dividend | 2026-06-15 | 119.05 (-2.02%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 11:20 | 119.52 (-1.10%) | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-04 10:30 | 114.70 (-0.65%) | ||
| Oncology Investor Event | 2026-06-01 18:00 | 118.72 (-0.78%) | ||
| General meeting for 2026 | 2026-05-26 09:00 | 122.41 (+1.54%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 09:00 | 110.95 (+2.21%) |
Show
Entries
Merck & Co Inc Frequently Asked Questions
What is Merck & Co Inc(MRK)'s stock price today?
The current price of MRK is $121.27. The 52 week high of MRK is $130.29 and 52 week low is $76.66.
When is next earnings date of Merck & Co Inc(MRK)?
The next earnings date of Merck & Co Inc(MRK) is 2026-08-04.
Does Merck & Co Inc(MRK) pay dividends? If so, how much?
The Dividend Yield %  of Merck & Co Inc(MRK) is 2.77% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(MRK) was 1.96. The lowest was 0.37. And the median was 0.47. The  Forward Dividend Yield % of Merck & Co Inc(MRK) is 2.81%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Merck & Co Inc
Headlines
See More- 1
Jul 10, 2026
Pfizer wins FDA label expansion for Padcev plus Merck’s Keytruda in bladder cancer
Seeking Alpha • 9:52am
Jul 08, 2026
White House weighing contenders for FDA's top job
Seeking Alpha • 4:12pm
Jun 30, 2026
Bristol, Merck, AbbVie face House committee probe over China trials
Seeking Alpha • 1:52pm
RFK Jr. ends Emergency Use Authorizations for COVID-19 drugs
Seeking Alpha • 1:30pm
Jun 26, 2026
FDA commissioner contenders down to three - report
Seeking Alpha • 10:18am
Jun 25, 2026
Record-setting healthcare M&A activity to extend through H2: PwC
Seeking Alpha • 12:59pm
Jun 24, 2026
Merck gains EU approval of Keyruda, Padcev combo for bladder cancer
Seeking Alpha • 6:49am
Jun 21, 2026
Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus
Seeking Alpha • 8:05am
Jun 18, 2026
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
Benzinga • 10:29am
Jun 16, 2026
Merck and Protillion ink AI drug discovery deal worth up to $510M
Seeking Alpha • 10:42am
Jun 15, 2026
Merck, J&J, Bristol decline on proposed CMS drug price rule
Seeking Alpha • 11:32am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers